Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gilead Sciences (NQ:GILD)

108.91 -1.17 (-1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher
BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer. 
Via Benzinga
Earnings Scheduled For April 24, 2025
Via Benzinga
P/E Ratio Insights for Gilead Sciences
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
Exploring Gilead Sciences's Earnings Expectations
Via Benzinga
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Assessing Gilead Sciences: Insights From 15 Financial Analysts
Via Benzinga
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns. 
Via Benzinga
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence. 
Via Stocktwits
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive.
A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around
Via The Motley Fool
Topics ETFs Economy World Trade
Exposures Economy Tariff
Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs
The Time 100 list of the most influential people in the world includes Elon Musk, Mark Zuckerberg and several other CEOs of publicly traded companies. 
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
3 Reasons GILD is Risky and 1 Stock to Buy Instead
In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is Iovance Biotherapeutics a Millionaire-Maker?
Via The Motley Fool
Exposures Product Safety
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
From Gilead Sciences, Inc.
Via Business Wire
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Rule Breaker Investing: Essays From Yesterday, Vol. 7
Via The Motley Fool
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
2 Top Dividend Stocks That Could Set You Up for Life
Via The Motley Fool
Topics Government Initial Public Offering Intellectual Property
Exposures Intellectual Property Political Securities Market
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Amazon, Alphabet, KLA And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Intel's New CEO Outlines Recovery Strategy. Wall Street Remain Cautious.
Intel's new CEO, Lip-Bu Tan, offered his strategy for turning around the troubled chipmaker in a speech late Monday. But Intel stock fell. 
Via Investor's Business Daily
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities. 
Via MarketBeat
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.